English Polski
Vol 27, No 4 (2021)
Review paper
Published online: 2022-01-28

open access

Page views 5881
Article views/downloads 349
Get Citation

Connect on Social Media

Connect on Social Media

Thromboprophylaxis in patients with Covid-19

Acta Angiologica 2021;27(4):138-143.


Abstract For two years, the entire world has been grappling with the new challenge that is the Covid-19 pandemic. In December 2019 in China’s largest province, Wuhan, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to Covid-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomised trials.